...
mirm-img

Mirum Pharmaceuticals Inc, Common Stock

MIRM

NMQ

$42.39

-$0.05

(-0.12%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.04B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
327.56K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.16
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$23.14 L
$48.89 H
$42.39

About Mirum Pharmaceuticals Inc, Common Stock

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMIRMSectorS&P500
1-Week Return-2.12%-3.72%-0.05%
1-Month Return2.34%-1.85%2.75%
3-Month Return4.87%-11.4%7.4%
6-Month Return28.45%-4.41%10.47%
1-Year Return44.26%4.13%27.57%
3-Year Return183.17%0.3%29.56%
5-Year Return145.31%36.62%89.3%
10-Year Return220.89%106.81%206.09%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-11.00M19.14M77.06M186.37M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":5.9,"profit":true},{"date":"2021-12-31","value":10.27,"profit":true},{"date":"2022-12-31","value":41.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue324.00K623.00K1.90M12.37M47.04M[{"date":"2019-12-31","value":0.69,"profit":true},{"date":"2020-12-31","value":1.32,"profit":true},{"date":"2021-12-31","value":4.05,"profit":true},{"date":"2022-12-31","value":26.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(324.00K)(623.00K)17.23M64.69M139.34M[{"date":"2019-12-31","value":-0.23,"profit":false},{"date":"2020-12-31","value":-0.45,"profit":false},{"date":"2021-12-31","value":12.37,"profit":true},{"date":"2022-12-31","value":46.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(5.66%)90.06%83.94%74.76%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-6.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.21,"profit":true},{"date":"2023-12-31","value":83.02,"profit":true}]
Operating Expenses54.74M104.30M190.65M195.91M248.49M[{"date":"2019-12-31","value":22.03,"profit":true},{"date":"2020-12-31","value":41.97,"profit":true},{"date":"2021-12-31","value":76.72,"profit":true},{"date":"2022-12-31","value":78.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(54.74M)(104.30M)(173.41M)(131.22M)(109.15M)[{"date":"2019-12-31","value":-5474300000,"profit":false},{"date":"2020-12-31","value":-10429600000,"profit":false},{"date":"2021-12-31","value":-17341300000,"profit":false},{"date":"2022-12-31","value":-13122000000,"profit":false},{"date":"2023-12-31","value":-10915400000,"profit":false}]
Total Non-Operating Income/Expense4.44M2.26M72.24M(22.97M)(57.07M)[{"date":"2019-12-31","value":6.15,"profit":true},{"date":"2020-12-31","value":3.12,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-31.8,"profit":false},{"date":"2023-12-31","value":-79,"profit":false}]
Pre-Tax Income(52.53M)(103.26M)(83.95M)(142.07M)(162.42M)[{"date":"2019-12-31","value":-5253200000,"profit":false},{"date":"2020-12-31","value":-10326400000,"profit":false},{"date":"2021-12-31","value":-8395100000,"profit":false},{"date":"2022-12-31","value":-14207100000,"profit":false},{"date":"2023-12-31","value":-16242400000,"profit":false}]
Income Taxes21.00K6.00K37.00K(6.41M)991.00K[{"date":"2019-12-31","value":2.12,"profit":true},{"date":"2020-12-31","value":0.61,"profit":true},{"date":"2021-12-31","value":3.73,"profit":true},{"date":"2022-12-31","value":-646.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(52.55M)(103.27M)(83.99M)(135.66M)(163.41M)[{"date":"2019-12-31","value":-5255300000,"profit":false},{"date":"2020-12-31","value":-10327000000,"profit":false},{"date":"2021-12-31","value":-8398800000,"profit":false},{"date":"2022-12-31","value":-13566500000,"profit":false},{"date":"2023-12-31","value":-16341500000,"profit":false}]
Income From Continuous Operations(52.55M)(103.27M)(83.99M)(135.66M)(164.19M)[{"date":"2019-12-31","value":-5255300000,"profit":false},{"date":"2020-12-31","value":-10327000000,"profit":false},{"date":"2021-12-31","value":-8398800000,"profit":false},{"date":"2022-12-31","value":-13566500000,"profit":false},{"date":"2023-12-31","value":-16418700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(52.55M)(103.27M)(83.99M)(135.66M)(163.41M)[{"date":"2019-12-31","value":-5255300000,"profit":false},{"date":"2020-12-31","value":-10327000000,"profit":false},{"date":"2021-12-31","value":-8398800000,"profit":false},{"date":"2022-12-31","value":-13566500000,"profit":false},{"date":"2023-12-31","value":-16341500000,"profit":false}]
EPS (Diluted)(7.54)(4.08)(6.35)(4.02)(3.97)[{"date":"2019-12-31","value":-753.53,"profit":false},{"date":"2020-12-31","value":-408,"profit":false},{"date":"2021-12-31","value":-635,"profit":false},{"date":"2022-12-31","value":-402,"profit":false},{"date":"2023-12-31","value":-397,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MIRM
Cash Ratio 2.46
Current Ratio 3.34
Quick Ratio 3.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MIRM
ROA (LTM) -9.10%
ROE (LTM) -39.84%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MIRM
Debt Ratio Lower is generally better. Negative is bad. 0.65
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.35

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MIRM
Trailing PE NM
Forward PE 61.35
P/S (TTM) 6.63
P/B 8.77
Price/FCF 535
EV/R 6.74
EV/Ebitda NM

FAQs

What is Mirum Pharmaceuticals Inc share price today?

Mirum Pharmaceuticals Inc (MIRM) share price today is $42.39

Can Indians buy Mirum Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Mirum Pharmaceuticals Inc (MIRM) on Vested. To buy Mirum Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MIRM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Mirum Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Mirum Pharmaceuticals Inc (MIRM) via the Vested app. You can start investing in Mirum Pharmaceuticals Inc (MIRM) with a minimum investment of $1.

How to invest in Mirum Pharmaceuticals Inc shares from India?

You can invest in shares of Mirum Pharmaceuticals Inc (MIRM) via Vested in three simple steps:

  • Click on Sign Up or Invest in MIRM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Mirum Pharmaceuticals Inc shares
What is Mirum Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Mirum Pharmaceuticals Inc (MIRM) is $48.89. The 52-week low price of Mirum Pharmaceuticals Inc (MIRM) is $23.14.

What is Mirum Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Mirum Pharmaceuticals Inc (MIRM) is

What is Mirum Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Mirum Pharmaceuticals Inc (MIRM) is 8.77

What is Mirum Pharmaceuticals Inc dividend yield?

The dividend yield of Mirum Pharmaceuticals Inc (MIRM) is 0.00%

What is the Market Cap of Mirum Pharmaceuticals Inc?

The market capitalization of Mirum Pharmaceuticals Inc (MIRM) is $2.04B

What is Mirum Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Mirum Pharmaceuticals Inc is MIRM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top